Mission
Odylia Therapeutics is a nonprofit organization focused on developing therapies for rare diseases that currently have no available treatment. By utilizing a unique nonprofit drug development model, Odylia accelerates drug development timelines, reduces costs, and partners with patient advocates and academic researchers to bring hope to the underserved rare disease patient community.
Basic Information
Founded in
2017
EIN
82-2120760
Total Assets
$10.02 million
UN Sustainable Development Goals Supported
This organization contributes to the following United Nations Sustainable Development Goals. See the SDG page for more information.
At a Glance
Our Gene Therapy Pipeline
Learn about the innovative gene therapies Odylia is developing for rare diseases.
Brydge Solutions
Explore how Brydge Solutions is helping accelerate therapeutic efforts for rare diseases.
The Odylia Collective
Discover Odylia's initiatives to empower patient groups and research communities.
Our Programs
Gene Therapy Pipeline
A program focused on developing gene therapies for rare diseases that do not have existing treatments.
Learn MoreBrydge Solutions
An initiative aimed at helping increase the efficiency and success rates of drug development for rare diseases.
Learn MoreVolunteer Opportunities
Regulatory Affairs Support
Assist Odylia with navigating the regulatory landscape for drug development.
Graphic Design and Social Media Engagement
Help enhance Odylia’s outreach through graphic design and social media strategy.
Medical Writing
Contribute to the creation of medical documents and communications for Odylia.
MIP Score (Beta)
The MIP Score is in beta! We'd love any feedback you may have.
The MIP Score and it's methodology is purely used as a way to visualize how a nonprofits public financial data compares against others. It doesn't reflect the unique circumstances and impact that a nonprofit has.The MIP Score should never be used to say one charity is better than another.
Overall Score
63
70
/100
Program Expense Ratio
77.71%
12
/20
Program Revenue Growth
7.36%
16
/20
Leverage Ratio
0.009555
20
/20
Working Capital Ratio
11.46
20
/20
Fundraising Efficiency
0
2
/20
Latest Filing Data: Form 990
Fiscal Year:2022
Source:Source: Self-reported by organization
Financial Details
Revenue
| Category | Amount | Percentage |
|---|---|---|
| Contributions, Gifts, and Grants | 976.5K | 88.90% |
| Program Services | 107.4K | 9.77% |
| Investment Income | 14.56K | 1.33% |
| Sales of Non-Inventory Assets | 0 | 0.00% |
| Other Notable Sources | 0 | 0.00% |
| Total Revenue | 1.098M | 100.00% |
Related Nonprofits
Alagille Syndrome Alliance
Med Research
Eye ResearchThe Association for Research in Vision and Ophthalmology
Med Research
Eye ResearchAmerican Ophthlmological Society Ch Aritable Educationa & Scientific
Med Research
Eye ResearchOdylia Therapeutics Inc.
Med Research
Eye ResearchBenign Essential Blepharospasm Research Foundation Inc.
Med Research
Eye Research